Saturday 17 October 2026
Export INBS’s income statement to Excel — free account
Intelligent Bio Solutions Inc.
INBS Healthcare Medical Devices
Intelligent Bio Solutions Inc.’s revenue for fiscal 2026 (year ended June 2026) was $4.2 million, up 38.1% from fiscal 2025. In the quarter to June 2026, revenue grew 51.1%, EPS grew 78.1% and free cash flow fell 31.6%, each against the same quarter a year earlier.
1.50
0.06
+4.17%
Follow INBS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.65 | 2.57 | 1.39 | 0.80 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.06) | (5.78) | (1.23) | (1.06) | |
P/B ratio |
2.54 | 0.83 | 0.61 | 0.64 | |
Price to Tangible BV |
0.00 | 1.19 | 0.93 | 1.36 | |
EV/Sales |
2.88 | 3.05 | 0.24 | 0.43 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.94) | (1.15) | (0.08) | (0.15) | |
EV/FCF |
(0.90) | (1.11) | (0.08) | (0.15) | |
Quick Ratio |
0.65 | 2.17 | 1.80 | 1.15 | |
Current Ratio |
0.89 | 2.37 | 2.11 | 1.44 | |
Net Debt/EBITDA |
0.61 | 0.32 | 2.44 | 1.12 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.30 | 0.27 | 0.32 | 0.42 | |
Operating CF/Net income |
0.95 | 0.59 | 1.51 | 0.81 | |
Capex/Depreciation |
0.00 | (0.30) | 0.04 | 0.00 | |
Interest Coverage |
(769.13) | (46.90) | (739.90) | 72.11 | |
Research and Development Expense of Revenue |
43.73% | 53.85% | 84.28% | 136.89% | |
Selling, General and Administrative Expense of Revenue |
239.23% | 241.05% | 231.77% | 283.92% | |
Intangible Assets out of Total Assets |
0.35 | 0.19 | 0.20 | 0.23 | |
Share Based Compensation of Revenue |
1.08% | 6.35% | 2.28% | 9.08% | |
Graham Net Nets |
(0.24) | 0.60 | 0.68 | 0.13 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(166.67%) | (155.51%) | (364.78%) | (392.17%) | |
Free Cash Flow Yield |
(120.85%) | (107.16%) | (210.86%) | (360.81%) | |
Revenue per Share |
1.30 | 1.02 | 0.67 | 0.73 | |
Operating CF per Share |
(3.33) | (1.65) | (2.72) | (2.16) | |
Capex per Share |
0.00 | (0.10) | 0.01 | 0.00 | |
Free Cash Flow per Share |
(3.33) | (1.75) | (2.71) | (2.16) | |
Cash per Share |
1.94 | 0.78 | 4.30 | 2.71 | |
Shareholders Equity per Share |
4.01 | 11.45 | 5.49 | 3.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.01 | 11.45 | 5.49 | 3.59 | |
Free Cash Flow |
(2.85) | (1.67) | (4.32) | (3.18) | |
Working Capital |
(0.58) | 7.05 | 5.14 | 2.17 | |
Capital Expenditures |
— | (0.10) | 0.01 | 0.00 | |
Net Current Asset Value |
(2.13) | 5.41 | 3.64 | 0.45 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.10 | (0.01) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.43 | 5.50 | 1.24 | 1.49 | |
Average Payables |
2.91 | 2.67 | 2.48 | 4.33 | |
Average Inventory |
0.68 | 0.65 | 0.64 | 0.53 | |
Average Assets |
10.88 | 13.17 | 12.22 | 10.10 | |
Average Common Equity |
4.69 | 7.55 | 6.85 | 4.05 |
Columns are period end dates